AstraZeneca/Amgen's brodalumab branches out to psoriatic arthritis
This article was originally published in Scrip
AstraZeneca and Amgen have upped the ante in the burgeoning anti-IL17 field with positive Phase II data for their investigational compound brodalumab in the additional indication of psoriatic arthritis published in the New England Journal of Medicine and due to be presented at the EULAR meeting in Paris on 14 June. However, larger studies of longer duration are necessary to assess adverse events associated with the product, the researchers said.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.